PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 1989European Journal of Cardio-Thoracic Surgery30 citations

Mechanical valve replacement in children and teenagers

View Full Paper
MAManuel J. AntunesKVKathy M. VanderdonckMSMichael R. Sussman

Key Result

Mechanical valve replacement in patients ≤20 years old with rheumatic valvular disease was associated with 6.3% early mortality and late mortality of 4.1% to 8.0% per patient-year depending on valve site (P<0.05).

Study Design

Type

Cohort (n=352)

Multicenter

No

Structured PICO

What are the long-term outcomes and complication rates of mechanical valve replacement in children and teenagers with rheumatic valvular disease?

P
Population
352 patients aged 20 years and younger with rheumatic valvular disease undergoing mechanical valve replacement, followed for a total of 1171 patient-years.
E
Exposure
Mechanical valve replacement (177 mitral, 62 aortic, 113 double) with Medtronic-Hall or St. Jude prostheses, followed by oral anticoagulation
O
Outcome
Early and late mortality, reoperation, thrombotic obstruction, systemic thromboembolism, and prosthetic endocarditishard clinical

Mechanical valve replacement in children and teenagers with rheumatic heart disease carries significant risks of late mortality and valve-related complications, particularly in those requiring double valve replacement.

Main Result

p-value: p=<0.05

Abstract

A previous study from this unit showed that only 19% of children with mitral bioprostheses were free from complications after 7 years and prompted us to review the performance of new-generation mechanical prostheses implanted in the same population group. In a 5-year period (1980-1985), 352 patients 20 years old and younger (mean age 15.3 +/- 4 years) with rheumatic valvular disease had 177 mitral, 62 aortic and 113 double (mitral + aortic) valve replacements with Medtronic-Hall or St. Jude prostheses. The overall early mortality was 6.3%. All survivors, followed up for a total of 1171 patient-years, received oral anticoagulation. The late mortality for mitral, aortic and double valve replacement was 4.1% per patient-year, 4.3% per patient-year and 8.0% per patient-year, respectively (P less than 0.05), and was valve-related in 46% of the cases. Twenty-nine patients, all but 2 in the mitral and double valve replacement groups, were reoperated upon (2.5% per patient-year), mainly for infective endocarditis (34%), for prosthetic thrombosis (33%) and for bland periprosthetic leak (31%). The incidence of thrombotic obstruction was 1.1% per patient-year: mitral valve replacement, 1.0% per patient-year; aortic valve replacement 0.5% per patient-year; and double valve replacement, 1.7% per patient-year; P less than 0.05) and was fatal in 33% of the cases. Major systemic thromboembolism occurred at the rate of 1.4% per patient-year, similar in the three groups. The incidence of prosthetic endocarditis was 0.9% per patient-year.(ABSTRACT TRUNCATED AT 250 WORDS)

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Antunes et al. (1989) conducted a cohort in Rheumatic valvular disease (n=352). Mechanical valve replacement (Medtronic-Hall or St. Jude prostheses) was evaluated on Late mortality (p=<0.05). Mechanical valve replacement in patients ≤20 years old with rheumatic valvular disease was associated with 6.3% early mortality and late mortality of 4.1% to 8.0% per patient-year depending on valve site (P<0.05).

synapsesocial.com/papers/6aa0ce77b6ff41cbc45b842ehttps://doi.org/10.1016/1010-7940(89)90070-5
Ask AI
Helpful
Bookmark
Share
View Full Paper